

Index

abdominal pain, <i>See also</i> pelvic pain after defecation, 74–5 in pregnancy, 86–8, 99–103, 106–9 IVF egg retrieval and, 187–9 ovarian cancer, 290–3 ovarian cyst, 142 pediatric, 244–6 positive hCG with no sexual activity and, 132 post-PID treatment, 71–3 sudden-onset right lower quadrant pain, 29–30 tamoxifen therapy and worsening, 117 urinary frequency and intermittent, 274–6 vaginal birth after Cesarean (VBAC) and acute, 139–40 worsening cyclic pain and amenorrhea in adolescent, 226–8	adenocarcinoma, 125 endometrial, 117, 278 ovarian, 275–6, 287–9 adenoma malignum, 125 adenomyosis, 125, 130 adhesiolysis, 215–16 adolescents, <i>See</i> pediatric/adolescent gynecology adoption, 235–6 adrenal insufficiency, 197 airbags, pregnancy and, 173 amenorrhea primary, 199–202 secondary, 203–6, 214–16 worsening cyclic pain and, 226–30 amniocentesis, cytomegalovirus (CMV), 185–6 amoxicillin chlamydia, 69 vulvar abscess, 123 ampicillin, septic abortion, 148–9 anastrozole, 117 androgen excess, 205, 208–10, 212 androgen insensitivity syndrome (AIS), 201 anemia, 1, 211, 237–9 anovulation differential diagnosis, 207–8 endometrial hyperplasia, 52–4 endometrial polyp, 115 irregular bleeding requiring transfusion, 211–13 polycystic ovary syndrome (PCOS), 207 primary amenorrhea, 201 secondary amenorrhea, 205	prolapsing submucous myoma, 1, 3 prophylactic use in abortion, 15, 87 septic abortion, 148–9 trichomonas infection, 20–2 tubo-ovarian abscess (TOA), 71–3 urinary tract infection (UTI), 259 vulvar abscess, 123 anticoagulation therapy, 34–5, 287–9 anti-D immune globulin (Rh(D) immune globulin), 82, 87, 110, 168, 173 anti-emetics, 18, 160, 162, 164 antihistamines, nausea and vomiting management, 159–60, 162, 164 anti-NMDA-receptor antibodies, 5–6 anti-NMDA-R encephalitis, 5–6 antiphospholipid antibody syndrome (APS), 194–5 antiviral therapy herpes simplex virus (HSV), 45–6, 48, 56 influenza, 181–2 Asherman syndrome (intrauterine adhesions (IUA)), 214–16 aspirin, 194 atrophic vaginitis, 37–40 avidity testing, 185 azithromycin, 69 azole therapy, 27–8 bacterial vaginosis (BV), 134 Bartholin’s gland, abscess, 123, 136–8 bazedoxifene/conjugated estrogen (BZA/CE), 39 bed rest, threatened abortion, 110 behavioral problems, 241–3 benzathine penicillin (Bicillin), 169–70	beta-blockers, thyroid storm management, 153 bleeding (vaginal/uterine), <i>See also</i> menstrual periods; spotting, vaginal after termination, 13–15 endometrial hyperplasia, 52–4, 190–2 following D&C for molar pregnancy, 282–4 heavier and longer menstrual periods, 60–2 heavy bleeding after medically managed missed abortion, 83 in a 75-year-old, 37–40 in pregnancy, <i>See</i> pregnancy irregular bleeding, 52–4, 190–2, 207–13 long-acting reversible contraception (LARC) and, 126–7 midcycle spotting and worsening menorrhagia, 113–16 polycystic ovary syndrome (PCOS), 208–10 postmenopausal women on tamoxifen, 119 prepubescent, 220–2 profuse vaginal bleeding in 65-year-old, 278–81 prolapsing submucous myoma and heavy, 1–3 requiring transfusion, 211–13 retained foreign body, 135 von Willebrand disease (VWD), 237–9 blocked duct, breast, 176 blood transfusion heavy bleeding after medically managed missed abortion, 84 irregular bleeding requiring, 211–13 body mass index (BMI), emergency contraception pills (ECPs), 18 bowel evisceration, 74–5
---	---	---	---

Index

- bowel obstruction
 small (SBO), 290–3
 vaginal birth after Cesarean (VBAC) and strangulated hernia, 139–40
breast abscess, 176–7
breast cancer
 estrogen therapy and history of, 39
 ovarian cancer risk, 143
 tamoxifen therapy and uterine mass, 117–19
breast engorgement, 176, 179
breast pain
 fever and unilateral, 175–7
 nipple pain postpartum, 178–80
breastfeeding
 fever and unilateral breast pain, 175–7
 lactational mastitis, 175–7
 nipple pain postpartum, 178–80
breathing problems, sudden-onset, 34–6
bullae, 49
butoconazole, 27

CA 125, 144, 275–6
calcium gluconate, 294–5
candidiasis (thrush), 26–8, 179
carbon dioxide laser ablation, 286
carboprost tromethamine, 149
carcinosarcoma, 279
cardiac arrest, 4, 172
cefotetan, 66, 72
cefoxitin
 pelvic inflammatory disease (PID), 66
 post-abortion infection, 15
 tubo-ovarian abscess (TOA), 71–2
ceftriaxone, 15, 66
cellulitis, vulvar, 49
cephalexin, 123, 177, 259
cerebrospinal fluid analysis, 4, 6
cervical agenesis, 230
cervical bleeding, 68
cervical cancer, 125, 271–3
cervical cysts, 124–5
cervical discharge,
 mucopurulent, 63, 68,
 See also vaginal discharge
cervical mass, 120–1, 124–5, 271–3
cervical polyps, 120–1, 125
cervical pregnancy, 89–91
cervical ulceration, 247
cervicitis, chlamydia, 68–70
Cesarean delivery
 perimortem, 172–4
 trial of labor after Cesarean (TOLAC), 140
 vaginal birth after (VBAC), 139–40

chancre, genital, 170
chemotherapy
 anticoagulation therapy, 289
 cervical cancer, 273
 choriocarcinoma, 283–4
 endometrial cancer, 280
 ovarian cancer, 287, 294–6
chest pain, 34
chest x-ray
 choriocarcinoma, 283
 influenza, 181
child sexual abuse, 221, 224, 241–3
Chlamydia trachomatis infection, 68–70
chlorpromazine, 164
cholestyramine, 153
choriocarcinoma, 283–4
chromosomal abnormalities,
 recurrent pregnancy loss (RPL), 194–5
Chvostek's sign, 295
cidofovir, 56
clavulanate, 123
clindamycin
 abscesses, 72, 123
 desquamative inflammatory vaginitis (DIV), 24–5
 pelvic inflammatory disease (PID), 66
 post-abortion infection, 15
 septic abortion, 148–9
clobetasol propionate, 42
clomiphene citrate, 205, 210
clotrimazole, 27
coagulopathy, 35, 212
 von Willebrand disease (VWD), 237–9
colposcopy, 286
combined oral contraceptives (COCs)
 anovulatory bleeding, 211–13
 corpus luteal cyst risk decrease, 146
 emergency contraception, 10, 17–18
 endometrial hyperplasia, 52
 venous thromboembolism (VTE), 34–6
 von Willebrand disease (VWD), 239
computed tomography (CT)
 bowel obstruction, 292
 cervical cancer, 272
 contrast venography, 34
 cystic teratoma, 5
 endometrial hyperplasia, 117
 ovarian torsion, 30
 pelvic inflammatory disease (PID), 65
 pulmonary angiogram (CTPA), 34–5
 strangulated hernia and small bowel obstruction, 139–40

trauma in pregnancy, 173
tubo-ovarian abscess (TOA), 71
 urogram, 261–2
condyloma lata, 169–70
cone biopsy, 273
constipation, 142–3
contraception, *See also specific drugs/drug types/devices*
 adolescents, 235–6
 emergency (EC), 10–12, 17–19
 long-acting reversible (LARC), 10–12, 97, 126–7, 236
 post-abortion, 16, 96–7
 pre-abortion statistics, 96
copper intrauterine device, 10–12, 17–18, 31
cornual pregnancy, 93
cornual resection, 95, 103–4
cornuostomy, 93, 95
corpus luteum cyst, 99, 101, 132, 146–7
corticosteroids, nausea and vomiting management, 164
cough, 181–2
 blood-tinged, 34
counseling, undesired pregnancy, 97
cranberry supplements, 259
cystadenocarcinoma, 275
cystitis, 258–60
cystocele, 247
cystourethrography, 252, 254, 256
cystourethroscopy, 262
cysts
 corpus luteum, 99, 101, 132, 146–7
 Nabothian, 124–5
 paratubal, 244
 ruptured hemorrhagic ovarian, 145–7
 simple ovarian, 142–4
 theca lutein, 156–7, 283
 vaginal, 58–9
cytomegalovirus (CMV), 184–6

dalteparin, 288–9
DDAVP (1-desamino-8-D-arginine vasopressin), 239
D-dimer levels, 288
debridement, necrotizing fasciitis, 49–51
deep venous thrombosis (DVT), 287–9, *See also* venous thromboembolism (VTE)/thromboembolic disease
defecation, pain after, 74–5
dehydration, hyperemesis gravidarum, 164
dehydroepiandrosterone (DHEA), 39
desquamative inflammatory vaginitis (DIV), 23–5

diabetes
 emergency contraception, 10–12
 recurrent pregnancy loss (RPL), 195
diagnostic peritoneal lavage (DPL), 173
diatrizoic acid (DA), 290
dicloxacillin, 175, 177
dilation and curettage (D&C)
 anovulatory bleeding, 212
 ectopic pregnancy, 91
 missed abortion, 81–4, 193
 molar pregnancy, 78, 157, 282–4
 spontaneous abortion, 87
dimenhydrinate, 160, 164
dinoprostone, 149
distal tube pregnancy, 93–4
diverticulectomy, 254
Doppler ultrasonography
 cervical mass, 125
 ovarian torsion, 30
 simple ovarian cyst, 142
 venous thromboembolism (VTE), 35, 287–8
double decidual sign, 110–11
doxycycline
 abscesses, 71–2, 123
 chlamydia, 69
 pelvic inflammatory disease (PID), 66
 post-abortion infection, 15
 prophylactic use in abortion, 15, 87
doxylamine, 159–60, 164
droperidol, 164
dysmenorrhea, 8, 217–19
dyspareunia, 38–40

ectocervical polyp, 121
ectopic pregnancy
 cervical, 89–91
 distal tube, 93–4
 interstitial, 93–5, 103
 ruptured, 106–8
 small unruptured, 99–102
 thyroid storm and, 152–3
 unruptured advanced, 103–5
 vaginal spotting in early pregnancy evaluation, 167
electric suction
 septic abortion, 149
 surgical abortion, 97
electroencephalography (EEG),
 anti-NMDA-R encephalitis, 6
electrolyte abnormalities, 294–6
emergency contraception (EC), 10–12, 17–19
emesis, *See* nausea and vomiting
encephalitis, anti-NMDA-R, 5–6
endocervical polyp, 120–1
endometrial ablation, 129–31

Index

- endometrial adenocarcinoma, 117
endometrial biopsy/sampling
 endometrial cancer, 278
 endometrial hyperplasia, 53–4, 190–1
 irregular bleeding requiring transfusion, 211–12
 polycystic ovary syndrome (PCOS), 205
endometrial cancer, 278–81
 endometrial hyperplasia progression to, 52–3, 191
 endometrial polyps and risk of, 113–14
 prolonged unopposed estrogen risk, 212
 tamoxifen therapy-related, 117–19
endometrial changes, tamoxifen-induced, 117–19
endometrial hyperplasia, 52–4, 113, 190–2, 205, 212
 tamoxifen-induced, 117–19
endometrial intraepithelial neoplasia (EIN), 191
endometrial polyps, 113–19
endometriosis, 130, 219
 acute exacerbation of, 7
endometritis, post-abortion, 13–16
endotracheal (ET) intubation, 173
enoxaparin, 288–9
enteral tube feeding, 162, 164
enterocele, 247
epithelial cyst (Nabothian cyst), 124–5
epsilon aminocaproic acid, 239
Epsom’s salts, 123
erythema, 49
erythromycin, chlamydia, 69
Escherichia coli, septic abortion, 149
estimated gestational age (EGA), calculation of, 167
estradiol vaginal cream, 38–9
estrogen levels
 hyperemesis gravidarum and, 163
estrogen therapy, *See also specific medications*
 anovulatory bleeding, 211–13
 cervical ulceration and topical, 247
 genital trauma and topical, 224
 gonadal dysgenesis, 201
 labial adhesions and topical, 231–2
 pessary devices and concomitant topical, 250
 urethral prolapse and topical, 267–8
 vaginal atrophy and topical, 249
 vulvovaginal atrophy (VVA), 39
 estrogen/progesterone therapy, 202
 etonogestrel (Nexplanon) contraceptive implant, 126–7
 expectant management
 ectopic pregnancy, 101
 interstitial pregnancy, 95
 missed abortion, 81, 84
 spontaneous abortion, 87
 Expedited Partner Therapy (EPT), 69
 factor VIII, 238–9
 famciclovir, 46, 48, 56
 fatigue, 196–8, 237, 294–6
 fetal pole, ultrasound, 167–8
 fetomaternal hemorrhage, 173
 fever
 after first-trimester termination, 13–15
 breast pain and, 175–7
 during laparoscopy, 151–3
 in pregnancy, 148–9, 181–3
 pelvic pain and, 63–7
 fibroid (leiomyoma), 61–2, 125
 extrauterine, 256–7
 FIGO staging
 cervical cancer, 272–3
 choriocarcinoma, 284
 endometrial cancer, 280
 vulvar cancer, 270
 finasteride, 210
 fluconazole, 27–8
 flu-like symptoms, in first-trimester, 184–6
 fluorescent treponemal antibody absorption test (FTA-ABS), 170
 flutamide, 210
 focused abdominal sonography for trauma (FAST), 173
 follicle-stimulating hormone (FSH), 200–1
 fondaparinux, 288–9
 foreign body, retained, 134–5, 220–1
 foscarnet, 56
 fosfomycin, 259
 Gartner duct cyst, 58–9
 Gellhorn pessary, 247, 250
 gentamicin
 pelvic inflammatory disease (PID), 66
 post-abortion infection, 15
 septic abortion, 148–9
 tubo-ovarian abscess (TOA), 72
 gestational sac, ultrasound, 110–11, 166, 168
 gestational trophoblastic disease (GTD), 78, 156
 gestational trophoblastic neoplasia (GTN), 156–8, 283–4
 molar pregnancy, 78–9, 151–3, 282–4
 GnRH deficiency, 201
 gonadal dysgenesis/primary ovarian insufficiency (POI), 201, 203
 gonadotropin deficiency, 197
 gonadotropin treatment, ovarian hyperstimulation syndrome (OHSS), 187–9
 growth hormone deficiency, 197
 halo sign, 100
 head trauma, fetal, 174
 heat therapy
 acute exacerbation of chronic pelvic pain, 1, 7
 dysmenorrhea, 8
 hematocolpos, 226–7, 229–30
 hematoma, vulvar, 224
 hematometra, 226, 229
 central, 130
 cornual, 130
 hematosalpinx, 130
 heparin
 antiphospholipid antibody syndrome, 194
 venous thromboembolism (VTE), 34–5, 287–9
 Herlyn–Werner–Wunderlich syndrome (obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome, 217–19
 hernia, strangulated, 139–40
 herpes simplex virus (HSV), 44–6
 HIV and persistent, 55–6
 recurrent infection, 46–8
 heterophilic antibodies, 132–3
 hirsutism, 208–10, 212
 history (patient), early pregnancy, 167
 HIV/AIDS, persistent herpes simplex virus (HSV), 55–6
 Homan’s sign, 288
 human chorionic gonadotropin (hCG) levels
 choriocarcinoma, 283–4
 early pregnancy assessment, 167–8
 ectopic pregnancy, 91, 95, 99–102, 104, 107–8
 hyperemesis gravidarum and, 163
 molar pregnancy, 78–9, 157
 positive test with no sexual activity, 132–3
 urinary pregnancy testing, 127
 human chorionic gonadotropin (hCG) treatment, 187–9
 human papillomavirus (HPV), 270, 272
 hydatidiform mole, *See* molar pregnancy
 hydrocortisone, 24–5, 153
 hydrosalpinx, 64
 hydroxyzine, 43
 hymenal laceration, 241
 hymenectomy, 227
 hyperemesis gravidarum, 156, 162–5
 hyperkalemia, 189
 hypertension
 and first-trimester bleeding, 155–8
 emergency contraception requirement, 10–12
 hyperthyroidism, 151–3
 molar pregnancy, 78
 hypoalbuminemia, 295
 hypocalcemia, 294–6
 hypogonadotropic hypogonadism, 200–3
 hypomagnesemia, 294–5
 hypotension, in pregnancy, 106–8
 hysterectomy
 cervical cancer, 273
 ectopic pregnancy, 91, 95
 endometrial cancer, 280
 endometrial hyperplasia, 54
 leiomyoma, 61
 molar pregnancy, 78, 156–8
 ovarian cancer, 276
 post-ablation tubal sterilization syndrome (PATSS), 129–30
 post-hysterectomy vesicovaginal fistula (VVF), 261–3
 prolapsing submucous myoma, 2–3
 urinary leakage following, 261–3
 vaginal cuff dehiscence, 74–5
 hysteroscopic resection, endometrial polyp, 115–16
 hysteroscopy
 endometrial cancer, 280
 endometrial polyps, 115, 117
 intrauterine adhesions (IUA), 215–16
 ibuprofen
 acute exacerbation of chronic pelvic pain, 7–8
 dysmenorrhea, 8
 imaging, *See specific techniques*
 imiquimod cream, 286
 immunoglobulin G (IgG) antibodies, 185
 immunoglobulin G (IgG) response, cytomegalovirus (CMV), 185
 immunoglobulin M (IgM) antibodies, 185

Index

- immunoglobulin M (IgM)
 response, cytomegalovirus (CMV), 185
- imperforate hymen, 200–1, 226–8, 230
- implantable contraception, 126–7
- in-vitro fertilization (IVF),
 ovarian hyperstimulation syndrome (OHSS), 187–9
- incision and drainage (I&D),
 abscess, 123, 136–7
- inclusion cyst, 58–9
- incontinence ring pessary, 249–50
- infection, *See also specific infections*
 post-abortal, 13–16
- infertility treatment
 endometrial hyperplasia and, 192
 ovarian hyperstimulation syndrome (OHSS), 187–9
- influenza, in pregnancy, 181–3
- insurance, emergency
 contraception issues, 11
- International Federation of
 Obstetricians and Gynaecologists (FIGO)
 staging, *See* FIGO staging
- interstitial line sign, 94
- interstitial pregnancy, 93–5, 103
- intrauterine adhesions (IUA)
 (Asherman syndrome), 214–16
- intrauterine device (IUD)
 after abortion, 16
 copper, 10–12, 17–18, 31
 expulsion, 32
 levonorgestrel, *See*
 levonorgestrel intrauterine device (LNG-IUD)
 pelvic inflammatory disease (PID), 63, 66–7
 pelvic x-ray of extrauterine, 31
 removal, 32–3
 string not visible, 31–3
- introital stenosis, 38
- intubation, 173
- iodine, thyroid storm
 management, 153
- itching, 20, 26–8, 41–3, 120
- Jarisch–Herxheimer reaction, 171
- Jod-Basedow effect, 153
- Kallmann syndrome, 201
- karyotype analysis, recurrent
 pregnancy loss (RPL), 193
- KCl, intraamniotic injection, 91
- KUB (kidneys, ureters, and
 bladder) x-ray, 290–2
- labial adhesions, 231–3
- labor, trial of labor after Cesarean
 (TOLAC), 140
- lactated Ringer’s solution, 173
- laparoscopy
 acute fever and tachycardia
 during, 151–3
 ectopic pregnancy, 94, 103, 106
 ovarian torsion, 244–5
 post-ablation tubal
 sterilization syndrome (PATSS), 129
 ruptured hemorrhagic ovarian
 cyst, 146
- lasofoxifene, 39
- leg pain, 287–9
- leiomyoma (fibroid), 61–2, 125
 extrauterine, 256–7
- leiomyosarcoma, 61
- leucovorin, 101, 104
- levofloxacin, chlamydia, 69
- levonorgestrel, emergency
 contraception (EC), 11, 17–18
- levonorgestrel intrauterine device
 (LNG-IUD), 31
 emergency contraception, 11
 endometrial ablation
 alternative, 130
 endometrial hyperplasia, 52–4, 191–2
 polycystic ovary syndrome (PCOS), 11
 von Willebrand disease (VWD), 239
- lichen planus, erosive vulvar, 24
- lichen sclerosus, 42–3, 221, 286
- lithium carbonate, 153
- long-acting reversible
 contraception (LARC),
 10–12, 97, 126–7, 236, *See*
 also specific methods
- lubricants, vaginal, 39–40
- lumbar puncture, 4, 6
- luteinizing hormone (LH), 17
- lymphadenectomy, 273
- lymphadenopathy, syphilis, 170
- magnesium sulfate, 123, 294
- magnetic resonance (MR)-
 guided focused ultrasound
 (MRgFUS), 62
- magnetic resonance imaging
 (MRI)
 anti-NMDA-R encephalitis, 6
 cervical mass, 125
 endometrial hyperplasia,
 117
 foreign body (retained), 135
 obstructed hemivagina and
 ipsilateral renal anomaly
 (OHVIRA) syndrome, 217
 ovarian torsion, 244–5
 periurethral masses, 254–6
- prolapsing submucous
 myomas, 30
- Sheehan syndrome, 196–7
- transverse vaginal septum, 229
- marsupialization, 137
- mastitis, lactational/puerperal,
 175–7, 179
- maternal mortality, septic
 abortion, 149
- Mayer–Rokitansky–Küster–
 Hauser syndrome
 (Mullerian agenesis),
 199–202, 230
- medroxyprogesterone acetate
 (MPA)
 anovulatory bleeding, 213
 dysmenorrhea, 8
 endometrial hyperplasia, 52–4, 190–2
 polycystic ovary syndrome (PCOS), 208
- mefenamic acid, 8
- megestrol, 191–2
- menorrhagia, 60–2, 113–16
- menstrual outflow obstruction,
 200–1, 217–19, 226–30
- menstrual periods
 amenorrhea, *See* amenorrhea
 dysmenorrhea, 8, 217–19
 irregular, 190–2, 207–10, 234–6
 menorrhagia, 60–2, 113–16
 von Willebrand disease (VWD) and heavy, 237–8
- mental status, pelvic mass and
 altered, 4–6
- metformin, 205
- methicillin-resistant
 Staphylococcus aureus
 (MRSA)
 Bartholin’s abscess, 137
 necrotizing fasciitis, 50
 vulvar abscess, 123
- methimazole, 153
- methotrexate, ectopic pregnancy,
 91, 94–5, 99, 101–2, 104
- methylprednisolone, 164
- metoclopramide, 159–60, 164
- metronidazole
 pelvic inflammatory disease
 (PID), 65–6
 post-abortal infection, 15
 prophylactic use in abortion,
 15
 trichomonas infection, 20–2
 tubo-ovarian abscess (TOA),
 71–2
- miconazole, 26–7
- microhemagglutination assay for
 Treponema pallidum
 (MHA-TP), 170
- micronized progesterone, 54
- microperforate hymen, 226–7
- midurethral sling surgery (MUS),
 264–6
- mifepristone, 97
- misoprostol
 abortion in undesired
 pregnancy, 97
 missed abortion, 81, 83–4
 septic abortion, 149
 spontaneous abortion, 87
- missed abortion, 80–2, 193–5
 heavy bleeding after medical
 management, 83–5
- molar pregnancy, 78–9, 151–3, 282–4
- morcellation, prolapsing
 submucous myoma, 2
- motor vehicle accident, during
 pregnancy, 172–4
- mucocolpos, 227
- mucopurulent discharge, 63, 68
- Mullerian agenesis, 199–202, 230
- Mullerian duct, developmental
 abnormalities, 218
- muscle cramps, 294–6
- myomas, prolapsing submucous,
 1–3
- myomectomy, 1–3, 61
- Nabothian cyst, 124–5
- nasogastric tube (NGT), 290, 292
- nausea and vomiting
 and abdominal pain in ovarian
 cancer, 290–3
 at eight weeks’ gestation,
 159–60
 hyperemesis gravidarum, 156, 162–5
 with fever and malaise in first
 trimester, 181–3
- necrotizing fasciitis, 49–51
- Nexplanon contraceptive
 implant, 126–7
- nipple pain, postpartum,
 178–80
- nipple shield, 179
- nipples, cracked, 178–80
- nitrofurantoin, 259, 264
- non-steroidal anti-inflammatory
 drugs (NSAIDs),
 dysmenorrhea, 218
- norethindrone (NET), 8
- norethisterone, 191–2
- nucleic acid amplification tests
 (NAATs), 68
- nystatin, 27
- obstructed hemivagina and
 ipsilateral renal anomaly
 (OHVIRA) syndrome,
 217–19
- ofloxacin, chlamydia, 69
- oligohydramnios, 148
- ondansetron, 162, 164
- oophorectomy, ruptured
 hemorrhagic ovarian cyst,
 146
- opioid medication, 7–8

Index

- oral contraceptives (OC)
 combined, *See* combined oral contraceptives (COCs)
 dysmenorrhea, 8, 218
 emergency contraception pills (ECP), 10–11, 17–19
 pelvic pain and extended cycle, 7–8
 polycystic ovary syndrome (PCOS), 203, 205, 208–9
 oseltamivir, 181–2
 ospemifene, 39
 ovarian cancer, 275–6
 electrolyte abnormalities, 294–6
 ovarian cyst and risk of, 142–4
 pediatric ovarian torsion risk, 246
 pelvic and leg pain, 287–9
 small bowel obstruction (SBO), 290–3
 ovarian cyst
 ruptured hemorrhagic, 145–7
 simple, 142–4
 ovarian hyperstimulation syndrome (OHSS), 187–9
 ovarian teratoma, 4, 6
 ovarian torsion, 29–30, 157, 244–6
 ovulation induction, 205, 210
 oxygen saturation, trauma in pregnancy, 173
 oxytocin, 149
- PALM-COEIN, 115, 211
 panhypopituitarism, 196
 paracentesis, 189
 parasthesias, 294–6
 parathyroid hormone (PTH), 295
 paratubal cyst, 244
 pediatric/adolescent gynecology
 anemia, 237–9
 imperforate hymen, 226–8
 irregular menses and weight gain, 234–6
 labial adhesions and urinary retention, 231–3
 lower abdominal pain, 244–6
 obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome, 217–19
 ovarian torsion, 244–6
 prepubescent vaginal bleeding, 220–2
 retained foreign body, 135, 220–1
 sexual abuse, 221, 224, 241–3
 straddle injury, 223–5
 teen pregnancy, 96–8, 234–6
 transverse vaginal septum, 229–30
 vulvar irritation and behavioral problems, 241–3
- worsening cyclic pain and amenorrhea, 226–30
 worsening dysmenorrhea, 217–19
 pelvic abscess, 66
 post-abortion, 14–15
 tubo-ovarian abscess (TOA), 65–6, 71–3, 99–100
 pelvic fluid, free, 145–7
 pelvic inflammatory disease (PID), 12, 63–7
 cervicitis assessment for, 69
 persistent pain and fever after treatment, 71–3
 pelvic mass, *See also specific conditions*
 altered mental status and, 4–6
 enlarging, 60–2
 Pelvic Organ Prolapse Quantification (POP-Q) system, 248
 pelvic pain, *See also* abdominal pain
 acute exacerbation of chronic, 7–9
 amenorrhea and worsening cyclic, 229–30
 and leg pain in ovarian cancer, 287–9
 cyclic pain after endometrial ablation, 129–31
 dysmenorrhea, 8, 217–19
 fever and, 63–7, 148–9
 free fluid in pelvis and, 145–7
 in pregnancy, 148–9
 post-abortion, 13–15
 penicillin, 169–70
 percutaneous umbilical cord blood sampling (PUBS), 186
 perineal laceration, 223
 periurethral/urethral mass, 252–7, 267–8
 pessary devices, 247–8
 incontinence after placement, 249–51
 pituitary gland
 primary amenorrhea, 201–2
 Sheehan syndrome, 196–8
 pivmecillinam, 259
 placental abruption, 173
 polycystic ovary syndrome (PCOS), 203–11
 polymerase chain reaction (PCR) testing, 45, 47, 56, 186
 polypectomy, 115–16, 121
 polyps
 cervical, 120–1, 125
 endometrial, 113–19
 prolapsing, 2
 postpartum hemorrhage, 196–8
 potassium iodide (SSKI), 153
 preeclampsia, 156–8
 pregnancy
 abdominal pain, 86–8, 99–102, 106–8
 abortion, *See* abortion
 chlamydia treatment, 69
 cornual, 93
 cytomegalovirus (CMV), 184–6
 ectopic, *See* ectopic pregnancy
 false-positive human chorionic gonadotropin (hCG) test, 132–3
 fever and pelvic pain, 148–9
 fever, malaise, nausea and vomiting, 181–3
 flu-like symptoms, 184–6
 herpes simplex virus, 48
 hypertension, 155–8
 hypotension, 106–8
 influenza in, 181–3
 molar, 78–9, 151–3, 282–4
 motor vehicle accident during, 172–4
 nausea and vomiting, 159–60, 162–5, 181–3
 Nexplanon contraceptive implant and, 126–7
 positive rapid plasma reagin (RPR) test, 169–71
 pregnancy testing, 11, 127
 recalcitrant severe vaginal discharge and odor, 134
 recurrent pregnancy loss (RPL), 193–5
 tachycardia, 77–9
 teen, 96–8, 234–6
 trial of labor after Cesarean (TOLAC), 140
 ultrasound abnormalities, 89–91, 93–5
 undesired, 96–8
 vaginal bleeding/spotting (first trimester), 80–2, 86–8, 93–5, 109–12, 155–8, 166–8
 vaginal bleeding/spotting (second trimester), 77–9
 von Willebrand disease (VWD), 239
 pregnancy loss, *See also* abortion
 recurrent (RPL), 193–5
 Premarin cream, 231–2
 primary ovarian insufficiency (POI)/gonadal dysgenesis, 201, 203
 probenecid, 15
 prochlorperazine, 164
 procidentia, 247–8
 progesterone levels
 ectopic pregnancy, 100
 hyperemesis gravidarum and, 163
 progesterone/progestin therapy, *See also specific drugs*
 anovulatory bleeding, 212–13
 endometrial hyperplasia, 53–4
 estrogen/progesterone therapy, 202
 threatened abortion, 110
 progestin challenge, 201, 203
 prolactin levels, 194–5, 201
 prolactinoma, 202
 prolapse
 urethral, 267–8
 uterine, 247–8
 vaginal wall, 256
 promethazine, 159–60, 162, 164
 propranolol, 153
 propylthiouracil (PTU), 153
 prostaglandins, 218
 pruritus (itching), 20, 26–8, 41–3, 120
 pseudogestational sac, 100, 167–8
 psychotic symptoms, pelvic mass and, 4–6
 pulmonary embolism (PE), 34–6, *See also* venous thromboembolism (VTE)/thromboembolic disease
 pyridoxine, 159–60, 164
- radiation therapy
 cervical cancer, 273
 choriocarcinoma, 284
 endometrial cancer, 280
 radiofrequency thermal ablation (RFA), 62
 rapid plasma reagin (RPR) test, early pregnancy and positive, 169–71
 rectocele, 247
 recurrent pregnancy loss (RPL), 193–5
 renal agenesis, 217–19
 respiratory distress syndrome, 157
 retained products of conception (POC), 13, 15
 retention cyst, mucinous (Nabothian cyst), 124–5
 Rh(D) immune globulin (anti-D immune globulin), 82, 87, 110, 168, 173
 ring of fire, 100
- saline-infusion sonohysterogram (SIS), 113, 115
 salpingectomy
 ectopic pregnancy, 102–6, 108
 for sterilization, 130
 post-ablation tubal sterilization syndrome (PATSS), 130
 salpingo-oophorectomy, 276, 280
 salpingostomy
 ectopic pregnancy, 95, 102, 104–5, 108
 interstitial pregnancy, 95

Index

- screening
 - cervical cancer, 272
 - chlamydia, 69–70
 - endometrial cancer, 119
 - ovarian cancer, 143–4, 275
 - syphilis, 169–70
 - tamoxifen therapy and, 119
- seatbelt use, in pregnancy, 172–3
- selective estrogen receptor modulator (SERM), 39, 117
- sella, empty, 196–7
- sepsis
 - mastitis and, 177
 - vulvar infection and, 49–51
- septate hymen, 226–7
- septate uterus, 193–5
- septic abortion, 148–9
 - secondary amenorrhea after, 214–16
- serofast syphilis, 170
- sexual abuse, 221, 224, 241–3
- sexually transmitted infections,
 - See also specific infections*
 - copper IUD use, 11
 - sexual abuse-related, 243
- Sheehan syndrome, 196–8
- Shigella vaginitis*, 221
- silver nitrate, 137
- sitz baths, 123
- small bowel obstruction (SBO), 290–3
- spironolactone, 210
- spontaneous abortion, 86–8
- spotting, vaginal, 80–2, 89, 93–5, 109, 113–16, 148, 166–8
- squamous cell carcinoma (SCC), 43, 269–70, 285–6
- Staphylococcus aureus*
 - methicillin-resistant,
 - See* methicillin-resistant *Staphylococcus aureus* (MRSA)
 - vulvar abscess, 123
- sterilization, post-ablation tubal sterilization syndrome (PATSS), 129–31
- straddle injury, 223–5
- streptococcal vaginitis, 221
- stress urinary incontinence (SUI), urethral sling surgery, 264–6
- substance abuse, 8
- sulfamethoxazole, trimethoprim-, 123, 259, 274
- syphilis, 170–1
- tachycardia
 - and fever during laparoscopy, 151–3
 - and vaginal bleeding in pregnancy, 77–9
- tamoxifen
 - induced endometrial changes, 117–19
 - uterine mass in 40-year-old on, 117–19
- teen pregnancy, 96–8, 234–6
- teratoma, 4–5
- terconazole, 27
- termination, of pregnancy,
 - See* abortion
- theca lutein cyst, 156–7, 283
- thimerosal, 183
- threatened abortion, 109–12, 126
- thromboembolic disease,
 - See* venous thromboembolism (VTE)/thromboembolic disease
- thrombolytics, 35
- thrush (candidiasis), 26–8, 179
- thyroid function tests, 163
- thyroid hormone, 152–3, 194, 197
- thyroid-stimulating hormone (TSH), 194–6
- thyroid storm, 152–3
- thyroxine (T4), 153
- tinidazole, 20–2
- tinzaparin, 288
- tioconazole, 27
- tissue-selective estrogen complex (TSEC), 39
- total parenteral nutrition (TPN), 164
- toxic shock syndrome, 15
- tranexamic acid, 8, 213, 239
- transcervical sterilization, 130
- transvaginal ultrasound
 - choriocarcinoma, 283
 - corpus luteum cyst, 99, 101
 - ectopic pregnancy, 89, 93–4, 99–100, 106–7
 - endometrial cancer, 278, 280
 - endometrial polyp, 113, 115
 - hydrosalpinx, 64
 - intrauterine device (IUD, 32
 - leiomyoma, 61
 - molar pregnancy, 78
 - ovarian cancer, 274–5
 - ovarian torsion, 30, 244
 - pelvic inflammatory disease (PID), 64–5
 - ruptured hemorrhagic ovarian cyst, 146
 - simple ovarian cyst, 142, 144
 - spontaneous abortion, 86
 - tamoxifen-induced
 - endometrial changes, 118
 - threatened abortion, 110
 - urethral diverticula, 254
 - vaginal spotting in early pregnancy, 167–8
- transverse vaginal septum, 200–1, 229–30
- trauma
 - during pregnancy, 172–4
 - prepubescent vaginal bleeding, 221
 - straddle injury, 223–5
- Treponema pallidum* particle agglutination (TP-PA) assay, 170
- Treponema pallidum*, syphilis infection, 170–1
- trichomonas infection, 20–2, 24
- triiodothyronine (T3), 153
- trimethobenzamide, 160, 164
- trimethoprim-sulfamethoxazole, 123, 259, 274
- Trousseau’s sign, 295
- tubal sterilization, post-ablation tubal sterilization syndrome (PATSS), 129–31
- tubo-ovarian abscess (TOA), 65–6, 71–3, 99–100
- Turner syndrome, 201
- ulceration
 - cervical, 247
 - vulvar, 41–3, 55
- ulipristal acetate (UPA), 10, 17–19
- ultrasound
 - cytomegalovirus (CMV), 184–6
 - D&C guidance, 193
 - Doppler, *See* Doppler ultrasonography
 - early pregnancy spotting and unusual, 93–5
 - ectopic pregnancy, 103
 - focused abdominal sonography for trauma (FAST), 173
 - missed abortion, 80
 - molar pregnancy, 151–2, 157
 - MR-guided focused ultrasound (MRgFUS), 62
 - ovarian hyperstimulation syndrome (OHSS), 188
 - periurethral mass, 256
 - polycystic ovary syndrome (PCOS), 203, 205, 207
 - primary amenorrhea, 199, 201
 - retained products of conception (POC), 13
 - secondary amenorrhea, 203, 205
 - septic abortion, 148
 - syphilis in pregnancy, 170–1
 - transvaginal, *See* transvaginal ultrasound
 - tubo-ovarian abscess (TOA), 72
 - unanticipated findings at prenatal visit, 89–91
 - vaginal spotting in early pregnancy, 166
- urethral caruncles, 268
- urethral diverticulum, 252–4, 268
- urethral prolapse, 267–8
- urethral sling surgery, 264–6
- urethral/periurethral mass, 252–7, 267–8
- urethrography, retrograde positive pressure, 256
- urethroscopy, 254
- urinalysis, UTI, 258–9
- urinary catheterization
 - post-hysterectomy vesicovaginal fistula (VVF), 262
 - urinary retention in genital herpes simplex virus (HSV), 45
 - voiding dysfunction (VD) after midurethral sling surgery (MUS), 264–5
- urinary frequency, intermittent abdominal pain and, 274–6
- urinary incontinence
 - following pessary placement, 249–51
 - leakage following hysterectomy, 261–3
 - new-onset, 258–60
 - urethral sling surgery, 264–6
- urinary retention, 44–6, 224
- labial adhesions and, 231–3
- urethral sling surgery and, 264–6
- urinary tract infection (UTI), 258–60, 274
- urogram, 261–2
- uterine abnormalities (structural)
 - recurrent pregnancy loss (RPL), 193–5
 - septate uterus, 193–5
 - uterine didelphys, 217–19
- uterine artery embolization (UAE), 61–2
- uterine bleeding, abnormal,
 - See* bleeding (vaginal/uterine)
- uterine didelphys with obstructed hemivagina and ipsilateral renal agenesis, 217–19
- uterine displacement, lateral, 173
- uterine mass, *See also specific conditions*
 - 40-year-old on tamoxifen, 117–19
- uterine perforation, 32
- uterine prolapse, 247–8
- vaccination
 - human papillomavirus (HPV), 272
 - influenza, 182–3
- vacuum aspiration
 - septic abortion, 149
- surgical abortion, 97
- vaginal atresia/agenesis, 230
- vaginal birth after Cesarean (VBAC), 139–40
- vaginal bleeding, *See* bleeding (vaginal/uterine)
- vaginal cuff dehiscence, 74–5

Index

vaginal cyst, 58–9	desquamative inflammatory (DIV), 23–5	voiding cystourethrography (VCUG), 252, 254, 256	vulvar pain
vaginal discharge, <i>See also</i> cervical discharge	recurrent unexplained symptoms, 23–5	voiding dysfunction (VD), 264–5	herpes simplex virus (HSV), 55–6
odor and recalcitrant severe, 134–5	<i>Shigella</i> , 221	volume resuscitation, 173, 188	urinary retention and, 44–6
prolapsing submucous myoma and malodorous, 1–2	streptococcal, 221	vomiting, <i>See</i> nausea and vomiting	vulvovaginal atrophy (VVA), symptomatic, 37–40
trichomonas infection, 20–1	vaginoscopy, 220–1	von Willebrand disease (VWD), 237–9	vulvovaginal candidiasis (VVC), 26–8
vulvovaginal candidiasis (VVC), 26–7	valacyclovir, 46, 48, 56	vulvar abscess, 122–3	
watery, 261	vascular endothelial growth factor (VEGF), 156	vulvar cancer, 269–70, 285–6	warfarin, 34–5, 287–9
vaginal dryness, 38–40	vena cava filter, 35, 289	vulvar cellulitis, 49	weight gain, and irregular menses, 234–6
vaginal itching, 26–8, 120	venereal disease research laboratory (VDRL) test, 169	vulvar erosive lichen planus, 24	Wolffian duct, developmental abnormalities, 218
vaginal lavage, 221	venous thromboembolism (VTE)/thromboembolic disease	vulvar hematoma, 224	World Health Organization (WHO) hyperplasia system, 191
vaginal pain	ovarian cancer and, 287–9	vulvar infection, <i>See also specific infections</i>	
and abdominal pain after defecation, 74–5	ovarian hyperstimulation syndrome (OHSS), 188–9	sepsis and, 49–51	yolk sac, ultrasound, 110–11, 168
recurrent herpes simplex virus (HSV), 47–8	ovarian torsion and, 246	vulvar intraepithelial neoplasia (VIN), 285–6	
vaginal wall prolapse, 256	sudden-onset shortness of breath, 34–6	vulvar irritation, and behavioral problems, 241–3	zanamivir, 182
vaginitis	vesicovaginal fistula (VVF), 261–3	vulvar itching, 20, 41–3	
atrophic, 37–40		vulvar mass, 122–3, 136–8, 269–70, 285–6, <i>See also specific conditions</i>	
candidal, 26–8			